The case for anti–IL-17 agents as first-line biologics in psoriatic arthritis

“The guidelines don’t give full credit to the anti–IL-17 agents.”

Several approaches recommended to reduce fillers, neuromodulator complications

The number of reported cases of vascular complications in patients receiving fillers has increased in recent years.

Expanded indications likely for apremilast

“My prediction is apremilast will have efficacy in children and teenagers comparable to what it has in adults.”

Treatment pipeline holds promise for rosacea

Recent studies of low-dose oral minocycline and topical encapsulated benzoyl peroxide show potential.

Merino wool clothing improves atopic dermatitis, studies find

In one study, the mean Eczema Area and Severity Index score in those initially randomized to merino wool improved from a mean baseline of 4.5 to 1.7 at week 6.

Sunscreen myths, controversies continue

At the end of the day, "the best sunscreen is the one a patient will use regularly and actually enjoy using."

Expert shares key facts about keloid therapy

Management of keloids after excision is mainly based on anecdotal evidence

COVID-19 risks in rheumatic disease remain unclear

Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more encouraging news for people living with rheumatic disease.

Data on potential risks of COVID-19 in psoriasis patients limited, but reassuring

For patients with psoriasis concerned about their outcome if infected with COVID-19, “there is no evidence to support stopping biologics or systemic agents.”

Strategic approach mitigates impact of antidrug antibodies in patients with rheumatic diseases

Consider dose escalation and adding an immunomodulator to overcome the impact of antidrug antibodies in rheumatic disease patients.

Pages